Trovagene Shows Promising Data for Lymphoma Treatment
Promising preclinical data
The CEO of Trovagene is optimistic and excited about the preclinical data for PCM 075 that was announced on August 21, 2017. He said "We are excited to see the synergistic benefits with PCM-075 in combination with a HDAC inhibitor in the most difficult cell lines in NHL. This data complements our recent announcement of an in-vivo study demonstrating synergy of PCM-075 with a leading investigational FLT3 inhibitor, as well as PCM-075 synergy with many chemotherapeutics. We have an active Investigational New Drug (IND) in place with the FDA for each of solid tumors and hematologic malignancies, which could facilitate the development of PCM-075 across a number of cancer types."
